Results of a pilot study led by investigators at @MSKCancerCenter showed that interleukin-18 “armored” CAR T cells targeting CD371 were effective at treating relapsed/refractory acute myeloid #leukemia at low doses. @BloodPortfolio @DaniyanMd @AbdelWahablab Learn more:

Congratulations to @DaniyanMd & team from @MSKCancerCenter on publication of the initial data from AML patients treated with IL-18 secreting CD371 CAR T cells @MSK. https://t.co/1Ai6kwl7HR 3 / 5 patients experienced MRD-negative morphologic leukemia free state.

Excited to announce a new paper in @CD_AACR with @junwei_s, @TomZhendong, @DaniyanMd and led by @PuZhang09980432. We perform screens of GAPs and GEFs in AML and discover a hematopoietic-specific GAP (ARHGAP45) required in AML: https://t.co/sxxdNVQyt1

I am very excited to share our latest work which is now out in JCI! We developed a transgenic mouse model to study the cooperativity of Trp53 and Tet2 LOF co-mutations in driving leukemic transformation with immune suppressive microenvironment. The mouse model phenocopies AML

Despite efforts to understand, we still do not know how to use it. A survey-review of the current landscape of immune monitoring procedures in CAR-T cell therapies across EBMT-affiliated centers. 👇@TheEBMT_CTIWP @AnnalisaRugger1 @JKuball @CChabannon https://t.co/9KZ1SXkn1x

Very nice @fredhutch presentation by #noamkopmar at Journal Watch about obe-cel versus brexu-cel as a CD19 CAR-T product in B-ALL. Love this graphic, including icon for a patient rebuilding their life after CAR-T! Cc @mshadman @DrShadeO @drjgauthier @AJPortuguese @RyanCassaday

Happy to share our new study in @natBME describing our “Zip-sort” strategy to purify dual-transduced cells with larger transgene payloads. Thanks to all our collaborators. @Parkerici @Cityofhope @MSKCancerCenter @Bushmanlab @VardhanaLab @KlebanoffLab https://t.co/kxk0d6cgm2. 1/

This is the table we’ve used (indication, common AEs, and black📦warnings) for approved #CART THERAPY w/ @Lymphoma_Doc & @SurbhiSidanaMD #AxiCel #BrexuCel #LisoCel #TisaCel #IdeCel #CiltaCel #mmsm #OncTwitter #lymsm #MedTwitter @OncoAlert #HemeTwitter #ASH24

Impromptu class of 2016 MSKCC reunion! #ASH24

#ASH24: Join leukemia specialist Dr. Mark Blain Geyer for his poster session on "CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion & Disease Clearance in Patients with Refractory Acute Myeloid Leukemia" today at @ASH_hematology. https://t.co/0dOnJJsFfS

Development incoming🔬 Our first URM Program grantee, Jennifer Lewis, has co-authored an abstract with Takeshi Fujino, from @MSKCancerCenter, on a CAR-T product that shows early promise in treating #AML. #ASH24 @LLSResearch

3- #AML #ALL #CARTRX #RNP https://t.co/kvo8urHjoI

5- #AML #CARTRX #CD371 https://t.co/rM6WKgR4cH

@zen_tropy Future AML therapeutic landscape will be less about ORR or CR, and more about MRD negativity, DOR and OS… nonetheless path forward for AFM28 could involve allo NK combo, or other chemo/HMA combos depending on population, still intriguing initial #AFM28 monotherapy activity $AFMD

Cytokine-mediated CAR T therapy resistance in AML

This guy just fulfilled everyone's childhood dream 🤩

Ok so I think at least two of these are pranks on tourists

U can butterfly your chicken drummies I was today years old.

https://t.co/1wLxbaRl7T

Let there be LIGHT! 💡 @MSKCancerCenter scientists including Dr. Winson Cai developed CAR T cells that overexpress LIGHT, a ligand of both LTβR on cancer cells and HVEM on immune cells, to overcome antigen heterogeneity. https://t.co/GmyA1Q8Y7r